A recent study by the researchers in the U.S. found that the FDA-approved medicine Sildenafil, popularly known as Viagra, might soon be used to treat Alzheimer's risk.
Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer's medication, Leqembi, and developing other treatments.
Next year’s Medicare Part B premiums are expected to be announced soon and there is speculation that coverage of another pricey new Alzheimer’s medication could cause monthly costs to go up, echoing what occurred in 2022. Leqembi received full approval from the Food and Drug Administration (FDA) in July, becoming the second drug of its…